Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.72 |
| ▸ | GAK | O14976 | 2/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.69 |
| ▸ | STK4 | Q13043 | 4/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132269 | 1.00 | EGFR (0.72) | EGFRGAKERBB2STK4FBP1 | |
| SCHEMBL29670932 | 1.00 | EGFR (0.72) | EGFRGAKERBB2STK4FBP1 | |
| SCHEMBL22419601 | 0.94 | EGFR (0.71) | EGFRGAKERBB2STK4SRC | |
| SCHEMBL2943166 | 0.90 | EGFR (0.85) | EGFRGAKERBB2SRC | |
| SCHEMBL3593063 | 0.90 | EGFR (0.86) | EGFRGAKERBB2SRC | |
| SCHEMBL20584416 | 0.87 | EGFR (0.71) | EGFRGAKERBB2STK4SRC | |
| SCHEMBL1897571 | 0.87 | EGFR (0.85) | EGFRGAKERBB2STK4 | |
| SCHEMBL29670935 | 0.85 | EGFR (0.67) | EGFRGAKERBB2STK4 | |
| SCHEMBL28487491 | 0.85 | EGFR (0.67) | EGFRGAKERBB2STK4 | |
| SCHEMBL14855133 | 0.84 | EGFR (0.66) | EGFRGAKERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490636-A | Heterocyclic compound and preparation method and application thereof | 苏中药业集团股份有限公司 | 2022-12-20 | — | — | CN | claimed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-111875539-A | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 江苏苏中药业集团股份有限公司 | 2020-11-03 | — | — | CN | claimed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | claimed |
| US-12017996-B2 | Substituted quinolines and formulations thereof | JIANGSU MEDOLUTION LTD (CN) | 2024-06-25 | — | — | US | disclosed |
| CN-116135844-A | Heterocyclic compound and preparation method and application thereof | 苏中药业集团股份有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-115490636-A | Heterocyclic compound and preparation method and application thereof | 苏中药业集团股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-115490636-A | Heterocyclic compound and preparation method and application thereof | 苏中药业集团股份有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-20220371999-A1 | SUBSTITUTED QUINOLINES AND FORMULATIONS THEREOF | JIANGSU MEDOLUTION LTD (CN) | 2022-11-24 | — | — | US | disclosed |
| CN-111875539-B | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 苏中药业集团股份有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-111875539-A | Preparation method of EGFR (epidermal growth factor receptor) molecular targeted antitumor drug | 江苏苏中药业集团股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-8765946-B2 | Methods of preparing and using quinazoline and quinoline derivatives | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2014-07-01 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
| US-7754729-B2 | Quinazoline and quinoline derivatives as irreversible protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-07-13 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2009-04-23 | — | — | US | disclosed |
| EP-2045245-A1 | INREVERSIBLE PROTEIN TYROSINE KINASES INHIBITORS AND THE PREPARATION METHODS AND USES THEREOF | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017996-B2 | Substituted quinolines and formulations thereof | MAP3K20, ABL1, MAP3K10 | EGFR 1594/4885GAK 308/4885ERBB2 307/4885 |
| US-20220371999-A1 | SUBSTITUTED QUINOLINES AND FORMULATIONS THEREOF | MAP3K20, ABL1, MAP3K10 | EGFR 1594/4885GAK 308/4885ERBB2 307/4885 |
| US-20090105247-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885GAK 390/4885ERBB2 170/4885 |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | EGFR 621/4885GAK 390/4885ERBB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.